ATC code None ChemSpider 28536139 3D model (Jmol) Interactive image | Legal status Investigational Formula C22H27ClFN7O4S Molar mass 540.011 g/mol | |
 | ||
Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.
It is a Selective BRAF Inhibitor, and is in phase III clinical trials.
Clinical trials
Several clinical trials of LGX818, either alone or in combinations with the MEK inhibitor MEK162, CDK4 inhibitor LEE011 are being run. The initial results are encouraging and were presented at ASCO 2013. As a result of a successful Phase Ib/II trials, Phase III trials are currently being initiated.
References
Encorafenib Wikipedia(Text) CC BY-SA